Organovo Holdings (FRA:4OR1) ROCE % : -173.70% (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Organovo Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Organovo Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -173.70%.

Organovo Holdings ROCE % Historical Data

The historical data trend for Organovo Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings ROCE % Chart

Organovo Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-69.68

-68.50

-49.57

-33.68

-74.40

Organovo Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-51.60	-153.30	-112.52	-147.28	-173.70

Organovo Holdings ROCE % Calculation

Organovo Holdings's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-16.561	/	( ( (30.233 - 1.256)	+	(18.972 - 3.429) )	/ 2 )
	=	-16.561	/	( (28.977	+	15.543)	/ 2 )
	=	-16.561	/	22.26
	=	-74.40 %

Organovo Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-13.5	/	( ( (10.458 - 1.499)	+	(8.144 - 1.559) )	/ 2 )
	=	-13.5	/	( ( 8.959	+	6.585 )	/ 2 )
	=	-13.5	/	7.772
	=	-173.70 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Organovo Holdings (FRA:4OR1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Organovo Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Organovo Holdings (FRA:4OR1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (FRA:4OR1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ONVO:USA 4OR1:Germany

Address

11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website

https://www.organovo.com

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Organovo Holdings (FRA:4OR1) Headlines

No Headlines